Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 9;74(1):1-8.
doi: 10.15585/mmwr.mm7401a1.

Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024

Miwako Kobayashi, Andrew J Leidner, Ryan Gierke, Wei Xing, Emma Accorsi, Pedro Moro, Mini Kamboj, George A Kuchel, Robert Schechter, Jamie Loehr, Adam L Cohen

Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024

Miwako Kobayashi et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Before October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a pneumococcal conjugate vaccine (PCV) for all adults aged ≥65 years, as well as for those aged 19-64 years with risk conditions for pneumococcal disease who have not received a PCV or whose vaccination history is unknown. Options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals) or 21-valent PCV (PCV21; CAPVAXIVE; Merck Sharp & Dohme) alone or 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme). There are additional recommendations for use of PCV20 or PCV21 for adults who started their pneumococcal vaccination series with 13-valent PCV (PCV13; Prevnar13; Wyeth Pharmaceuticals). The ACIP Pneumococcal Vaccines Work Group employed the Evidence to Recommendations framework to guide its deliberations on expanding the age-based PCV recommendation to include adults aged 50-64 years. On October 23, 2024, ACIP recommended a single dose of PCV for all PCV-naïve adults aged ≥50 years. Recommendations for PCVs among adults aged 19-49 years with risk conditions and PCV13-vaccinated adults have not changed from previous recommendations. This report summarizes evidence considered for these recommendations and provides updated clinical guidance for use of PCV.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Mini Kamboj reports receipt of payment from the Virginia Department of Health, travel support from Magic Oncology (University of Colorado), and uncompensated service as cochair of the American Society of Clinical Oncology guideline on vaccination of adults with cancer. George A. Kuchel reports grant support from the National Institutes of Health (Patient-Centered Outcomes Research Institute). No other potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Serotypes, included in pneumococcal vaccines currently recommended for adults — United States, 2024 Abbreviations: PCV = pneumococcal conjugate vaccine; PCV15 = 15-valent PCV; PCV20 = 20-valent PCV; PCV21 = 21-valent PCV; PPSV23 = 23-valent pneumococcal polysaccharide vaccine. * PCV21 is approved for the prevention of invasive pneumococcal disease caused by serotype 15B based upon prespecified criteria for the proportion of participants with fourfold or more rise in opsonophagocytic activity responses. https://www.fda.gov/media/179426/download?attachment † PCV21 contains serotype 20A.
See this image and copyright information in PMC

References

    1. CDC. Active bacterial core surveillance (ABCs): ABCs bact facts interactive data dashboard. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https://www.cdc.gov/abcs/bact-facts/data-dashboard.html
    1. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:1069–75. 10.15585/mmwr.mm6846a5 - DOI - PMC - PubMed
    1. Kobayashi M. Summary of work group interpretation of EtR and policy options: PCV use in adults aged ≥50 years [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 23, 2024. https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/04-Kobayashi-Pne...
    1. Food and Drug Administration. Package insert: PREVNAR 20. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https://www.fda.gov/media/149987/download?attachment
    1. Food and Drug Administration. Package insert: CAPVAXIVE. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https://www.fda.gov/media/179426/download?attachment

MeSH terms